{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:51:20Z","timestamp":1775879480401,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1016\/s0145-2126(00)00105-3","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T19:54:37Z","timestamp":1027626877000},"page":"227-235","source":"Crossref","is-referenced-by-count":48,"title":["Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells"],"prefix":"10.1016","volume":"25","author":[{"given":"Silvia","family":"Deaglio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Canella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germano","family":"Baj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Arnulfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Malavasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0145-2126(00)00105-3_BIB1","first-page":"337","article-title":"Differentiation agents in cancer therapy","volume":"15","author":"Ferrari","year":"1994","journal-title":"Cancer Chemother. Biol. Response Modif."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0163-7258(96)00120-9","article-title":"Differentiation, differentiation\/gene therapy and cancer","volume":"73","author":"Scott","year":"1997","journal-title":"Pharmacol Ther."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0925-5710(98)00043-7","article-title":"Differentiation therapy of leukemia: achievements, limitations and future prospects","volume":"68","author":"Hozumi","year":"1998","journal-title":"Int. J. Hematol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/9518","article-title":"Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia","volume":"5","author":"Charrad","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB5","first-page":"349","article-title":"Retinoids, neoplasia and differentiation therapy","volume":"17","author":"Lippman","year":"1997","journal-title":"Cancer Chemother. Biol. Response Modif."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB6","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1093\/jnci\/90.24.1866","article-title":"Scientists explore use of arsenic in therapy","volume":"90","author":"Miller","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6690312","article-title":"Retinoids: present role and future potential","volume":"80","author":"Evans","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev.med.47.1.555","article-title":"Pathogenesis and management of acute promyelocytic leukemia","volume":"47","author":"Warrell","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB9","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s001340050632","article-title":"Acute respiratory distress syndrome due to all-trans retinoic acid","volume":"24","author":"Gruson","year":"1998","journal-title":"Intensive Care Med."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB10","doi-asserted-by":"crossref","unstructured":"Deaglio S., Mallone R., Arnulfo A., Baj G., Surico N., Dianzani U., et al. CD38\/CD31, a receptor\/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol 2000;99\u2013120.","DOI":"10.1159\/000058765"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB11","first-page":"1746","article-title":"Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha","volume":"54","author":"Drach","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB12","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1096\/fasebj.10.12.8903511","article-title":"Human CD38, a cell-surface protein with multiple functions","volume":"10","author":"Mehta","year":"1996","journal-title":"FASEB J."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4049\/jimmunol.156.2.727","article-title":"Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells","volume":"156","author":"Deaglio","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB16","first-page":"3345","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells","volume":"89","author":"Chen","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.leu.2401112","article-title":"The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms","volume":"12","author":"Zhang","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB18","first-page":"1041","article-title":"Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients","volume":"59","author":"Rousselot","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0014-5793(99)00841-8","article-title":"Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro","volume":"455","author":"Akao","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB20","series-title":"Human leukocyte differentiation antigens","first-page":"p.151","article-title":"CD38 cluster report","author":"Morra","year":"1998"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.7079750","article-title":"Human myeloma cell line carrying a Philadelphia chromosome","volume":"216","author":"Karpas","year":"1982","journal-title":"Science"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/blood.V66.2.444.444","article-title":"Phenotypic and functional analysis of B cell lines from patients with multiple myeloma","volume":"66","author":"Goldstein","year":"1985","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB23","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4049\/jimmunol.160.3.1106","article-title":"Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells","volume":"160","author":"Cesano","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB24","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/sj.bjc.6690551","article-title":"The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acid","volume":"80","author":"Alexander","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00000441-187801000-00004","article-title":"Action of iron, cod-liver oil and arsenic on the globular richness of the blood","volume":"75","author":"Cutler","year":"1878","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB26","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJM199811053391909","article-title":"Arsenic\u2014new life for an old potion","volume":"339","author":"Gallagher","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB27","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB28","first-page":"195","article-title":"The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia","volume":"13","author":"Zhang","year":"1999","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB29","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","article-title":"In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha\/PML proteins","volume":"88","author":"Chen","year":"1996","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB30","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood.V92.5.1497","article-title":"Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner","volume":"92","author":"Wang","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/ijc.2910470521","article-title":"The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype","volume":"47","author":"Rivoltini","year":"1991","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB32","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.4049\/jimmunol.157.10.4347","article-title":"CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target cell susceptibility to promiscuous cytotoxic T cell lysis","volume":"157","author":"Nishio","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","article-title":"Human CD38: a glycoprotein in search of a function","volume":"15","author":"Malavasi","year":"1994","journal-title":"Immunol. Today"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB34","series-title":"Recent advances in CD38 and related molecules. Basel: Karger","year":"2000"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2141.1999.01321.x","article-title":"Human myeloma cells express the CD38 ligand CD31","volume":"105","author":"Vallario","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB36","first-page":"19","article-title":"Signaling and activation, calcium and cytokine release, receptorial activities of the human CD38 family of NAD+-converting ectoenzymes","volume":"2","author":"Deaglio","year":"1999","journal-title":"Res. Trends"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1615\/CritRevImmunol.v15.i2.40","article-title":"Lymphocyte adhesion to endothelium","volume":"15","author":"Dianzani","year":"1995","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB38","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.4049\/jimmunol.157.11.5097","article-title":"Cross-linking of intercellular adhesion molecule 1 (CD54) induces AP-1 activation and IL-1beta transcription","volume":"157","author":"Koyama","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/rtph.1999.1282","article-title":"A physiologically based pharmacokinetic model of inorganic arsenic","volume":"29","author":"Yu","year":"1999","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/S0145-2126(00)00105-3_BIB40","series-title":"VIII International Conference on Differentiation Therapy, Montr\u00e9al, 3\u20136, October","article-title":"Evaluation of arsenic trioxide in breast cancer therapy","author":"Baj","year":"1999"},{"key":"10.1016\/S0145-2126(00)00105-3_BIB41","first-page":"3065","article-title":"Arsenic trioxide-mediated growth inhibition in MC\/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis","volume":"60","author":"Park","year":"2000","journal-title":"Cancer Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212600001053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212600001053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T22:00:12Z","timestamp":1681336812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212600001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["S0145212600001053"],"URL":"https:\/\/doi.org\/10.1016\/s0145-2126(00)00105-3","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}